New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
08:11 EDTAMED, IMGN, SQNM, HITK, HTWR, MDAS, AEZS, CRVL, DSCI, CCRNOppenheimer to host a conference
23rd Annual Healthcare Conference is being held in New York on December 12-13 with webcasted presentations to begin on December 13 at 7:45 am; not all presentations may be webcasted. Webcast Link
News For AMED;DSCI;CRVL;AEZS;MDAS;HTWR;HITK;SQNM;IMGN;CCRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
07:48 EDTMDASLeerink to hold a roundtable
Subscribe for More Information
September 29, 2014
07:47 EDTMDASMedAssets a top trading idea into year end, says RW Baird
Subscribe for More Information
September 26, 2014
10:01 EDTCCRNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:34 EDTCCRNCross Country Healthcare upgraded to Buy from Neutral at UBS
Subscribe for More Information
September 24, 2014
07:41 EDTCCRNCross Country Healthcare management to meet with UBS
Group luncheons to be held in New York on September 24 at 12:30 pm and in Boston on September 25 at 12:30 pm hosted by UBS.
September 22, 2014
07:05 EDTSQNMSequenom presents new data supporting accuracy of MaterniT21 test
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, presented patient clinical data substantiating the performance of its MaterniT21 PLUS noninvasive prenatal test in the laboratory. An ad hoc analysis of 185,000 samples from patients at high-risk for fetal chromosome aneuploidy demonstrated stable positivity rates for trisomy 21, 18 and 13, which mirror the positivity rates found in large studies on high-risk populations utilizing invasive diagnostic procedures. Additionally, Sequenom Laboratories reported performance results from clinical testing with the MaterniT21 PLUS test with Enhanced Sequencing Series. In the ad hoc analysis based on voluntary outcomes provided by clinicians, the estimated sensitivity for trisomy 21, 18 and 13 were 99.3%, 98.3% and 97.4% respectively, and the estimated specificity was >99.9% for all three trisomies. These clinical laboratory performance data are equivalent to those published in the clinical validation studies of the MaterniT21 test. Based on these performance metrics, Sequenom Laboratories estimates that the MaterniT21 PLUS test positive predictive value for trisomy 21, 18 and 13 were 99.0%, 97.6% and 92.8% respectively, and the negative predictive value was >99.9% for all three trisomies.
September 19, 2014
09:05 EDTIMGNImmunoGen discloses Chief Medical Officer James O'Leary's intention to leave
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use